These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 25209873

  • 21. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG, Liu T, Buyue Y, Zhang X, Bitonti AJ, Pierce GF, Sommer JM, Jiang H, Peters RT.
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [Abstract] [Full Text] [Related]

  • 22. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.
    Kenet G, Chambost H, Male C, Lambert T, Halimeh S, Chernova T, Mancuso ME, Curtin J, Voigt C, Li Y, Jacobs I, Santagostino E, PROLONG-9FP Investigator Study Group.
    Thromb Haemost; 2016 Sep 27; 116(4):659-68. PubMed ID: 27583313
    [Abstract] [Full Text] [Related]

  • 23. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.
    Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, Cheng G, Thompson AR, Goyal J, Tubridy KL, Peters RT, Dumont JA, Euwart D, Li L, Hallén B, Gozzi P, Bitonti AJ, Jiang H, Luk A, Pierce GF.
    Blood; 2012 Jan 19; 119(3):666-72. PubMed ID: 22110246
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
    Négrier C, Abdul Karim F, Lepatan LM, Lienhart A, López-Fernández MF, Mahlangu J, Pabinger I, Li Y, Wolko D, Voigt C, Jacobs I, Santagostino E.
    Haemophilia; 2016 Jul 19; 22(4):e259-66. PubMed ID: 27333467
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice.
    Mancuso ME, Oldenburg J, Boggio L, Kenet G, Chan A, Altisent C, Seifert W, Santagostino E.
    Haemophilia; 2020 Jul 19; 26(4):637-642. PubMed ID: 32542961
    [Abstract] [Full Text] [Related]

  • 32. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
    Tortella BJ, Alvir J, McDonald M, Spurden D, Fogarty PF, Chhabra A, Pleil AM.
    J Manag Care Spec Pharm; 2018 Jul 19; 24(7):643-653. PubMed ID: 29363389
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice.
    van der Flier A, Hong V, Liu Z, Piepenhagen P, Ulinski G, Dumont JA, Orcutt KD, Goel A, Peters R, Salas J.
    Blood Coagul Fibrinolysis; 2023 Sep 01; 34(6):353-363. PubMed ID: 37577860
    [Abstract] [Full Text] [Related]

  • 36. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects.
    Valentino LA, Rusen L, Elezovic I, Smith LM, Korth-Bradley JM, Rendo P.
    Haemophilia; 2014 May 01; 20(3):398-406. PubMed ID: 24418368
    [Abstract] [Full Text] [Related]

  • 37. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.
    Oldenburg J, Yan S, Maro G, Krishnarajah G, Tiede A.
    Curr Med Res Opin; 2020 Jan 01; 36(1):9-15. PubMed ID: 31469321
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A, Abdul-Karim F, Carcao M, Persson P, Clausen WHO, Kearney S, Matsushita T, Negrier C, Oldenburg J, Santagostino E, Young G.
    Haemophilia; 2017 Jul 01; 23(4):547-555. PubMed ID: 28233381
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.